CLY-124
Sickle Cell Disease
Phase 1Active
Key Facts
About Cellarity
Cellarity is a private, AI-driven biotech founded in 2017 that is shifting the drug discovery paradigm from single-target to cell-state-focused therapeutics. Its core technology combines high-dimensional single-cell data with AI models to identify novel biological pathways and design oral compounds that correct dysfunctional cellular networks. The company has advanced its first candidate, CLY-124 for sickle cell disease, into clinical development and has established a strategic partnership with Novo Nordisk in metabolic disease, validating its platform's potential.
View full company profileTherapeutic Areas
Other Sickle Cell Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ANXV | Annexin Pharmaceuticals | Research |
| Oxbryta® (voxelotor) | Cleo Life Sciences | Approved |
| CT-101 | Cetya Therapeutics | Pre-clinical |
| Endari (L-glutamine oral powder) | Emmaus Life Sciences | Approved |
| Undisclosed | Biossil | Phase 2/3 |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Ramatroban (KAR101) | KARE Biosciences | Preclinical |
| Digital Model for Sickle Cell Disease | Koneksa Health | Development/Validation |
| ILX-002 | Illexcor Therapeutics | Pre-clinical |
| Epeleuton | Afimmune | Phase 2 |
| AB1 | AkiraBio | Pre-clinical |
| Oral Decitabine/Tetrahydrouridine | Novo Nordisk | Phase 2 |